Abstract
The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 system, a groundbreaking innovation in genetic engineering, has revolutionized our approach to surmounting complex diseases, culminating in CASGEVY™ approved for sickle cell anemia. Derived from a microbial immune defense mechanism, CRISPR/Cas9, characterized as precision, maneuverability and universality in gene editing, has been harnessed as a versatile tool for precisely manipulating DNA in mammals. In the process of applying it to practice, the consecutive exploitation of novel orthologs and variants never ceases. It's conducive to understanding the essentialities of diseases, particularly cancer, which is crucial for diagnosis, prevention, and treatment. CRISPR/Cas9 is used not only to investigate tumorous genes functioning but also to model disparate cancers, providing valuable insights into tumor biology, resistance, and immune evasion. Upon cancer therapy, CRISPR/Cas9 is instrumental in developing individual and precise cancer therapies that can selectively activate or deactivate genes within tumor cells, aiming to cripple tumor growth and invasion and sensitize cancer cells to treatments. Furthermore, it facilitates the development of innovative treatments, enhancing the targeting efficiency of reprogrammed immune cells, exemplified by advancements in CAR-T regimen. Beyond therapy, it is a potent tool for screening susceptible genes, offering the possibility of intervening before the tumor initiative or progresses. However, despite its vast potential, the application of CRISPR/Cas9 in cancer research and therapy is accompanied by significant efficacy, efficiency, technical, and safety considerations. Escalating technology innovations are warranted to address these issues. The CRISPR/Cas9 system is revolutionizing cancer research and treatment, opening up new avenues for advancements in our understanding and management of cancers. The integration of this evolving technology into clinical practice promises a new era of precision oncology, with targeted, personalized, and potentially curative therapies for cancer patients.
Introduction: The Precision Oncology Revolution
Cancer remains a multifaceted and often lethal disease, driven by a complex web of genetic mutations and a protective tumor microenvironment. Traditional therapies frequently struggle with tumor heterogeneity and acquired resistance. While early gene-editing tools like ZFNs and TALENs offered hope, they were often too cumbersome for widespread clinical use.
The emergence of CRISPR/Cas9 has transformed this landscape, evolving from a rudimentary bacterial defense mechanism into a sophisticated "Swiss Army knife" for precision oncology. This review tracks that metamorphosis, detailing how high-fidelity variants, base editors, and prime editors are moving beyond simple DNA cutting to enable the highly precise gene modulation required for next-generation cancer diagnostics, disease modeling, and personalized immunotherapy.
The Evolving CRISPR Toolkit
The transition from "molecular scissors" to a versatile scaffold has been driven by several key technical advancements reviewed in the literature:
- High-Fidelity Variants: Engineered versions of Cas9 (e.g., eSpCas9, Cas9-HF1, and HypaCas9) reduce non-specific DNA binding, significantly minimizing off-target activity.
- Expanded PAM Orthologs: By utilizing different bacterial species (like the smaller S. aureus for SaCas9) or engineering SpCas9-NG, researchers have broadened the range of genomic "docking" sites available for editing.
- Base and Prime Editors: These technologies allow for single-nucleotide conversions (C to T or A to G) or "search-and-replace" genetic writing without creating double-stranded breaks (DSBs), thereby avoiding unpredictable insertions or deletions (indels).
- CRISPRi/a: Using catalytically "dead" Cas9 (dCas9) to block (interference) or recruit (activation) transcriptional machinery allows for the toggling of gene expression without altering the underlying DNA sequence.
Clinical Applications and Key Insights
The field is moving toward using CRISPR as a scaffold for epigenetic and base-level modifications. Key areas of impact include:
- Immunotherapy and "Universal" CAR-T: CRISPR is being used to create "off-the-shelf" CAR-T cells by knocking out endogenous T-cell receptors (TCR) and HLA molecules. In some relapsed B-cell non-Hodgkin lymphoma trials (NCT04637763), CRISPR-targeted CAR-T cells achieved a 100% Objective Response Rate (ORR).
- Tumor Suppressor Activation: Rather than just knocking out oncogenes, researchers use CRISPRa to "wake up" dormant tumor suppressor genes (like MASPIN or REPRIMO), forcing cancer cells back into a non-proliferative state.
- Disease Modeling: CRISPR has drastically reduced the time and cost of creating complex animal models (e.g., EML4-ALK rearrangements) from years to months, providing deeper insights into tumor biology and resistance.
- Regulatory Proof of Concept: The approval of CASGEVY™ for sickle cell anemia serves as a landmark regulatory milestone, proving the safety and viability of CRISPR-based medicines.
Challenges and Future Directions
Despite its vast potential, several "formidable challenges" remain that necessitate further innovation:
- Immunogenicity: As Cas9 is bacterial in origin (S. pyogenes), the human immune system may recognize and attack the treatment.
- Delivery: Viral vectors (AAV) have limited cargo space, while non-viral nanoparticles struggle with deep tissue penetration in solid tumors.
- Safety: Concerns regarding "chromothripsis" (chromosome shattering) or long-term effects of unintended edits necessitate extended follow-up periods in clinical trials.
- Equity: The high cost of these therapies risks exacerbating "genetic inequality," where access is limited by economic status.
Conclusion
The integration of evolving CRISPR technology into clinical practice promises a new era of precision oncology. By addressing current technical and safety bottlenecks, the field is moving toward targeted, personalized, and potentially curative therapies that could redefine cancer management.
Summary updated